Table 1.
Baseline characteristics of the study cohort stratified by biochemical and clinical outcome
| Characteristicsa | Stratified by Biochemical Outcome | Stratified by Clinical Outcome | ||||
|---|---|---|---|---|---|---|
| Complete (n = 26) | Partial (n = 2) | Absent (n = 5) | Complete (n = 7) | Partial (n = 24) | Absent (n = 5) | |
| Age, mean (SD), years [n = 33; n = 36] | 54.9 (9.6) | 55.0 (13.6) | 53.6 (7.2) | 54.3 (9.2) | 54.4 (8.7) | 55.6 (13.4) |
| Age strata, no. (%) [n = 33; n = 36] | ||||||
| <40 years | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 40–49 years | 9 (35) | 1 (50) | 1 (20) | 3 (43) | 7 (29) | 2 (40) |
| 50–59 years | 10 (38) | 0 (0) | 3 (60) | 2 (29) | 10 (42) | 2 (40) |
| <60 years | 19 (73) | 1 (50) | 4 (80) | 5 (71) | 17 (71) | 4 (80) |
| ≥60 years | 7 (27) | 1 (50) | 1 (20) | 2 (29) | 7 (29) | 1 (20) |
| Male sex, no. (%) [n = 33; n = 36] | 24 (92) | 2 (100) | 4 (80) | 5 (71) | 21 (88) | 5 (100) |
| BMI, mean (SD), kg/m2 [n = 17; n = 18] | 32.1 (4.4) | ND | 29.1 (4.7) | 27.2 (2.9) | 32.1 (4.2) | 27.2 (5.5) |
| SBP, mean (SD), mm Hg [n = 33; n = 36] | 150 (20) | 139 (13) | 147 (12) | 149 (24) | 151 (17) | 140 (12) |
| DBP, mean (SD), mm Hg [n = 33; n = 36] | 92 (12) | 81 (6) | 89 (4) | 94 (13) | 92 (12) | 86 (8) |
| Medications, median (IQR), DDD [n = 33; n = 36] | 3.8 (3.7) | ND | 3.0 (5.9) | 4.0 (4.5) | 5.1 (3.3) | 1.5 (1.6) |
| PAC, median (IQR), pmol/L [n = 30; n = 32] | 648 (587) | ND | 572 (781) | 647 (619) | 589 (575) | 610 (1044) |
| ARR, median (IQR), % ULN [n = 32; n = 35] | 452 (1081) | ND | 635 (613) | 590 (1232) | 413 (1001) | 452 (540) |
| Serum potassium, mean (SD), mmol/L [n = 33; n = 36] | 3.0 (0.5) | 2.8 (0.1) | 3.0 (0.2) | 3.1 (0.6) | 3.0 (0.4) | 3.1 (0.2) |
| Hypokalemia (<3.6mmol/L), no. (%) [n = 33; n = 36] | 24 (92) | 2 (100) | 5 (100) | 6 (86) | 22 (92) | 5 (100) |
| Serum creatinine, mean (SD), µmol/L [n = 31; n = 34] | 90.3 (22.0) | ND | 97.5 (31.6) | 87.7 (24.8) | 91.0 (24.3) | 75.6 (14.8) |
| eGFR, mean (SD), mL/min/1.73 m2 [n = 31; n = 34] | 79.1 (20.4) | ND | 69.8 (16.6) | 77.0 (19.2) | 77.6 (19.7) | 96.9 (23.4) |
| AVS lateralization index, median (IQR) [n = 33; n = 36] | 16.1 (39.8) | ND | 20.9 (27.2) | 23.8 (68.4) | 12.5 (45.1) | 17.3 (9.5) |
Number of patients with missing data (no.; % of clinical outcomes group) included: BMI (18; 50%), PAC (4; 11%), ARR (1; 3%), creatinine (2; 6%), and eGFR (2; 6%). Number of patients with missing data (no.; % of biochemical outcomes group) included: BMI (16; 49%), PAC (3; 9%), ARR (1; 3%), creatinine (2; 6%), and eGFR (2; 6%).
Abbreviations: ARR, aldosterone-to-renin ratio; AVS, adrenal vein sampling; BMI, body mass index; DBP, diastolic blood pressure; DDD, defined daily dose; eGFR, estimated glomerular filtration rate; IQR, interquartile range; ND, no data; PAC, plasma aldosterone concentration; SBP, systolic blood pressure; SD, standard deviation; ULN, upper limit of normal.
a n shown for biochemical and clinical outcomes, respectively.